Search clinical trials for: Cytarabine,

Total 1306 results

Fondazione Italiana Linfomi ONLUS

Completed

Phase II Study of Age-Adjusted Rituximab, Bendamustine, Cytarabine as Induction Therapy in Older Patients With MCL (FIL-RBAC500)

Mantle Cell Lymphoma

Italy
Seagen Inc.

Completed

A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML

Acute Myeloid Leukemia

United States
Peking University Third Hospital

Not yet recruiting

the Efficacy and Safety of CLAE in R/R T-ALL/LBL

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
H. Lee Moffitt Cancer Center and Research Institute
Jazz Pharmaceuticals

Completed

Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Relapsed Acute Lymphoblastic Leukemia | Lymphoid Leukemia

United States
Keio University

Completed

Safety and Efficacy of Unrelated Cord Blood Transplantation for Adult Patients With Hematologic Malignancies

Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome | Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia

Japan
Sumitomo Pharma America, Inc.

Terminated

Study of Alvocidib in Patients With Relapsed/Refractory AML Following Treatment With Venetoclax Combination Therapy

Acute Myeloid Leukemia (AML)

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid Cancer

Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Neoplasms

United States
H. Lee Moffitt Cancer Center and Research Institute
Novartis

Completed

CLAG Gleevec in Relapsed or Refractory Acute Myeloid Leukemia (AML)

Leukemia

United States
Fred Hutchinson Cancer Center
Jazz Pharmaceuticals

Recruiting

CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients

Acute Myeloid Leukemia | Myeloid Neoplasm

United States
University of Maryland, Baltimore
Hematologics, Inc

Recruiting

CLAG-GO for Patients With Persistent, Relapsed or Refractory AML

Acute Myeloid Leukemia Recurrent | Acute Myeloid Leukemia, Adult | Acute Myeloid Leukemia, Relapsed, Adult

United States
University Hospital Muenster
Celgene Corporation; Amgen

Completed

Efficacy of 5-azacytidine Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) (AML-AZA)

Acute Myeloid Leukemia

Germany
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

FLT3 Gene Mutation Negative | FLT3 Internal Tandem Duplication Positive | Recurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic...

United States
AbbVie
Genentech, Inc.

Completed

A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia

AML | Acute Myelogenous Leukemia

United States, Australia, Germany, Italy
University Hospital Heidelberg
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Withdrawn

Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs Physician's Choice in Newly Diagnosed FLT3-ITD+ AML (Q-SOC)

Acute Myeloid Leukemia
Assistance Publique Hopitaux De Marseille

Unknown

Interest of a Therapeutic Follow-up of the Cytarabine in the Acute Myeloid Leukaemia: Is There Constitutional Biomarkers

Acute Myeloid Leukemia

France
GSO Global Clinical Research BV
Karyopharm Therapeutics Inc

Completed

A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia (Relapsed/Refractory)

Germany
PETHEMA Foundation
Dynamic Solutions

Completed

Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (FLUGAZA)

Acute Myeloid Leukemia

Spain
Biosuccess Biotech Co., Ltd.

Terminated

Safety and Efficacy Study of PD-616 Plus Cytarabine to Treat Acute Myelogenous Leukemia or Myelodysplastic Syndrome (AML/MDS)

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
M.D. Anderson Cancer Center
Jazz Pharmaceuticals

Withdrawn

Phase II Study of Fludarabine, Cytarabine (ARA-C) and Erwinase IV in Patients With Relapsed or Refractory Hematologic Malignancies

Hematologic Malignancy
University Hospital Muenster
Boehringer Ingelheim

Unknown

Phase I/II Trial: BIBF 1120 Added to Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

Germany
Moleculin Biotech, Inc.

Recruiting

Study of Liposomal Annamycin in Combination With Cytarabine for the Treatment of Subjects With Acute Myeloid Leukemia (AML)

Leukemia, Myeloid, Acute

Italy, Poland
Cardiff Oncology

Completed

Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome

Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Untreated Adult Acute Myeloid Leukemia | Myelodysplastic/Myeloproliferative Neoplasm | Myelodysplastic Syndrome With Isolated Del(5q)

United States
Hannover Medical School
Genzyme, a Sanofi Company

Unknown

Dose Escalation of Clofarabine in Combination With Cytarabine and Idarubicin as Induction Therapy in High Risk AML (CIARA)

Acute Myeloid Leukemia

Germany
Peking Union Medical College Hospital

Recruiting

IA14 Induction in Young Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
Eli Lilly and Company

Completed

A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Leridistim Compared With Filgrastim in Treating Older Patients With Acute Myeloid Leukemia

Leukemia | Anemia | Thrombocytopenia | Neutropenia

United States
Case Comprehensive Cancer Center

Recruiting

CPX-351 Therapy for MDS After Hypomethylating Agent Failure

Myelodysplastic Syndrome (MDS)

United States
Jonsson Comprehensive Cancer Center
Jazz Pharmaceuticals

Active, not recruiting

CPX-351 Plus Enasidenib for Relapsed AML

Recurrent Acute Myeloid Leukemia

United States
Novartis Pharmaceuticals

Completed

A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML

Acute Myeloid Leukemia

Japan, Taiwan, Hong Kong, Thailand, Korea, Republic of, Russian Federation, Vietnam
University of Nebraska
Millennium Pharmaceuticals, Inc.

Completed

VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma

Mantle Cell Lymphoma | Non-hodgkin's Lymphoma

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...

Terminated

Consolidation Therapy for Acute Myeloid Leukemia Guided by Leukemia Stem Cell Behavior

Acute Myeloid Leukemia

United States
Sumitomo Pharma America, Inc.

Completed

Ph I Study of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).

Acute Myeloid Leukemia

United States
National Cancer Institute (NCI)

Completed

Azacitidine in Combination With Mitoxantrone, Etoposide Phosphate, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
Hoffmann-La Roche

Completed

A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia

Myelogenous Leukemia, Acute

United States, Korea, Republic of, Australia, United Kingdom, Canada, France, Italy
Rondeep Brar
National Cancer Institute (NCI)

Completed

CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute Myeloblastic Leukemia Without Maturation (M1) | Adult Acute Myeloid Leukemia... and other conditions

United States
University Hospital, Bonn
Mundipharma Research GmbH & Co KG

Terminated

A Clinical Trial to Assess the Safety & Efficacy of the Treatment of Patients With Metastasis From Malignant Melanoma - Treatment Consists of the Substances Lomustine (Capsules) & Cytarabine (Injected Into an Area Near the Spinal Cord), Accompanied by Radiotherapy of the Brain

Leptomeningeal Metastasis From Malignant Melanoma

Germany
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
Centre Hospitalier Universitaire de Nice
Jazz Pharmaceuticals; Acute Leukemia French Association

Recruiting

CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics (ALFA2101)

Acute Myeloid Leukemia

France
European Organisation for Research and Treatment...
Gruppo Italiano Malattie EMatologiche dell'Adulto

Unknown

Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia (AML-14A)

Myelodysplastic Syndromes | Leukemia

Belgium, Croatia, France, Italy, Netherlands
Seoul National University Hospital

Completed

Modified-FLAI Induction and Consolidation Chemotherapy in Elderly Patient With Acute Myeloid Leukemia (AML) (m-FLAI)

Acute Myeloid Leukemia

Korea, Republic of
Mundipharma Research Limited

Completed

Study to Demonstrate the Safety of WBR Administered at the Same Time as Intrathecal Liposomal Cytarabine (DepoCyte®) Versus Intrathecal Liposomal Cytarabine (DepoCyte®) Administered After WBR for the Treatment of Solid Tumour Neoplastic Meningitis in Patients With or Without Brain Metastasis.

Brain Metastases | Solid Tumour Neoplastic Meningitis

Austria, Germany
Jazz Pharmaceuticals

Completed

Multicenter Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Cancer.

Hematologic Neoplasms

United States
The First Affiliated Hospital of Soochow University
Second Affiliated Hospital of Soochow University; The Second People's Hospital... and other collaborators

Unknown

Study of DAC Combined With HAAG Regimen in Newly Diagnosed Younger AML Patients

Acute Myeloid Leukemia | Induction Chemotherapy

China
ALZA

Unknown

Combination Chemotherapy in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia

United States
European Organisation for Research and Treatment...

Terminated

Combination Chemotherapy in Treating Children With Relapsed or Refractory Acute Lymphocytic Leukemia

Leukemia

France, Belgium, Portugal
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
Ohio State University Comprehensive Cancer Center

Active, not recruiting

Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma and other conditions

United States
St. Jude Children's Research Hospital
National Cancer Institute (NCI); Genzyme, a Sanofi Company

Completed

Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States, Singapore
Viron Therapeutics Inc
Vion Pharmaceuticals

Terminated

Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS)

United States

Search clinical trials for: Cytarabine,

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Greece

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations